Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -31.08% | -31.21% | 56.76% | -123.27% | 38.99% |
| Total Depreciation and Amortization | 6.37% | -2.59% | -48.74% | 153.55% | -7.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.02% | 464.36% | -93.06% | 34.85% | -29.11% |
| Change in Net Operating Assets | -80.97% | 23.13% | -62.86% | 253.45% | -5.82% |
| Cash from Operations | -258.33% | -40.59% | -47.07% | 24.43% | 71.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -20.94% | 493.27% | 37.55% | -20.55% | -56.92% |
| Total Debt Repaid | 59.52% | -1,091.93% | -10.41% | -2.05% | -1.96% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 75.29% | 161.06% | 50.89% | -29.42% | -69.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -100.00% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -121.33% | 3,268.42% | 322.22% | -88.16% | -12.64% |